Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.
|Articles|June 21, 2023
Pointers With Portela: Surviving Melanoma
Author(s)Dustin Portela, DO
In this week’s Pointers with Portela, the 208SkinDoc interviews a patient who has battled stage IV melanoma for many years.
Advertisement
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Advertisement
Related to this article
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.
Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.
Advertisement
Advertisement
Trending on Dermatology Times
1
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
2
Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema
3
Systemic Therapy Selection in Pediatric and Adult Atopic Dermatitis
4
Women’s Health Needs in Psoriasis and Atopic Dermatitis
5